Cooley M&A

OCTOBER 19, 2022

Some of the tax provisions contained in the legislation, including the 1% excise tax on certain stock buybacks, may impact special purpose acquisition companies (SPACs) at key points in their life cycle. Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals. DigitalOcean Agrees to Buy Cloudways.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion; and Roche’s acquisition of Carmot Therapeutics for up to $3.1

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

M&A Leadership Council

AUGUST 15, 2022

Few companies divest units immediately following an acquisition (unless they are compelled to do so by antitrust regulators), but many companies divest them eventually. In any given year, nearly half of the acquisitions that occur come about because the sellers are divesting a company unit. baby Bells”) to handle local calls.

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 30, 2024

Software companies with a target on their backs Public software companies (particularly those with mature revenue growth rates) are often ripe acquisition targets for mega cap tech and highly acquisitive, software focused private equity sponsors, and therefore present easy targets for “sell the company” campaigns by activists.

Private Equity 52

Private Equity M&A Capital Investors 52